๐Ÿ”ฌDeep Research

EQ โ€” Equillium Inc ยท catalysts, narrative & risks

ยท14 sourcesEQ forecast โ†’

Equillium Inc. (Nasdaq: EQ) โ€” Research Snapshot as of Oct 26, 2026

Equillium is a clinical-stage biotechnology company (La Jolla, CA) developing therapies for autoimmune and inflammatory disorders, currently focused on its lead candidate EQ504 (an oral, colon-targeted aryl hydrocarbon receptor [AhR] modulator for ulcerative colitis, plus an inhaled formulation for lung disease) and EQ302 (an oral bispecific IL-15/IL-21 inhibitor for celiac disease) [1], [4], [7], [15]. The stock last closed at ~$1.23 on Oct 23, 2026, with a market cap of ~$78M and no revenue [9], [11], [13].



AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’